Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 1
2007 4
2008 2
2010 4
2011 4
2013 2
2014 3
2015 3
2016 7
2017 7
2018 8
2020 4
2021 2
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: A nationwide CEREO study.
Groh M, Fenwarth L, Labro M, Boudry A, Fournier E, Wemeau M, Marceau-Renaut A, Daltro de Oliveira R, Abraham J, Barry M, Blanche P, Bodard Q, Braun T, Chebrek S, Decamp M, Durel CA, Forcade E, Gerfaud-Valentin M, Golfier C, Gourguechon C, Grardel N, Kosmider O, Martis N, Melboucy Belkhir S, Merabet F, Michon A, Moreau S, Morice C, Néel A, Nicolini FE, Pascal L, Pasquier F, Pieragostini A, Roche-Lestienne C, Rousselot P, Terriou L, Thiebaut-Bertrand A, Viallard JF, Preudhomme C, Kahn JE, Lefevre G, Duployez N; CEREO Collaborators. Groh M, et al. Among authors: moreau s. Am J Hematol. 2024 Apr 2. doi: 10.1002/ajh.27306. Online ahead of print. Am J Hematol. 2024. PMID: 38563187
New 2,4-bis[(substituted-aminomethyl)phenyl]phenylquinazoline and 2,4-bis[(substituted-aminomethyl)phenyl]phenylquinoline Derivatives: Synthesis and Biological Evaluation as Novel Anticancer Agents by Targeting G-Quadruplex.
Guillon J, Le Borgne M, Milano V, Guédin-Beaurepaire A, Moreau S, Pinaud N, Ronga L, Savrimoutou S, Albenque-Rubio S, Marchivie M, Kalout H, Walker C, Chevallier L, Buré C, Largy E, Gabelica V, Mergny JL, Baylot V, Ferrer J, Idrissi Y, Chevret E, Cappellen D, Desplat V, Schelz Z, Zupkó I. Guillon J, et al. Among authors: moreau s. Pharmaceuticals (Basel). 2023 Dec 25;17(1):30. doi: 10.3390/ph17010030. Pharmaceuticals (Basel). 2023. PMID: 38256866 Free PMC article.
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Talbot A, Bobin A, Tabone L, Lambert J, Boccaccio C, Deal C, Petillon MO, Allangba O, Agape P, Arnautou P, Belkhir R, Cailleres S, Chaoui D, Chrétien ML, Decaux O, Schulmann S, Frenzel L, Gastaud L, Huart A, Hulin C, Karlin L, Laribi K, Le Calloch R, Lenain P, Macro M, Manier S, Montes L, Moreau S, Moreau P, Morel V, Norwood J, Piocelle FO, Perrot A, Pica GM, Rey P, Schmitt A, Stoppa AM, Tiab M, Touzeau C, Vidal V, Vignon M, Vincent L, Van De Wyngaert Z, Zarnitsky C, Kerbouche N, Paka P, Leleu X, Arnulf B, Avet-Loiseau H, Du Myélome IIF. Talbot A, et al. Among authors: moreau s. Haematologica. 2023 Oct 1;108(10):2774-2782. doi: 10.3324/haematol.2022.281772. Haematologica. 2023. PMID: 37078253 Free PMC article.
Design, Synthesis, and Antiprotozoal Evaluation of New Promising 2,9-Bis[(substituted-aminomethyl)]-4,7-phenyl-1,10-phenanthroline Derivatives, a Potential Alternative Scaffold to Drug Efflux.
Guillon J, Cohen A, Boudot C, Monic S, Savrimoutou S, Moreau S, Albenque-Rubio S, Lafon-Schmaltz C, Dassonville-Klimpt A, Mergny JL, Ronga L, Bernabeu de Maria M, Lamarche J, Lago CD, Largy E, Gabelica V, Moukha S, Dozolme P, Agnamey P, Azas N, Mullié C, Courtioux B, Sonnet P. Guillon J, et al. Among authors: moreau s. Pathogens. 2022 Nov 13;11(11):1339. doi: 10.3390/pathogens11111339. Pathogens. 2022. PMID: 36422591 Free PMC article.
Design, synthesis, and antiproliferative effect of 2,9-bis[4-(pyridinylalkylaminomethyl)phenyl]-1,10-phenanthroline derivatives on human leukemic cells by targeting G-quadruplex.
Guillon J, Denevault-Sabourin C, Chevret E, Brachet-Botineau M, Milano V, Guédin-Beaurepaire A, Moreau S, Ronga L, Savrimoutou S, Rubio S, Ferrer J, Lamarche J, Mergny JL, Viaud-Massuard MC, Ranz M, Largy E, Gabelica V, Rosu F, Gouilleux F, Desplat V. Guillon J, et al. Among authors: moreau s. Arch Pharm (Weinheim). 2021 Aug;354(8):e2000450. doi: 10.1002/ardp.202000450. Epub 2021 Apr 14. Arch Pharm (Weinheim). 2021. PMID: 33852185
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
Letestu R, Dahmani A, Boubaya M, Baseggio L, Campos L, Chatelain B, Debliquis A, Drénou B, Jacob MC, Legac E, Le Garff-Tavernier M, Lhoumeau AC, Quiney C, Robillard N, Ticchioni M, Aanei C, Katsahian S, Delepine R, Vaudaux S, Rouillé V, Béné MC, Dartigeas C, Van Den Neste E, Leprêtre S, Feugier P, Cartron G, Leblond V, Lévy V, Cymbalista F; French Innovative Leukemia Organization (FILO). Letestu R, et al. Leukemia. 2021 Jun;35(6):1597-1609. doi: 10.1038/s41375-020-01009-z. Epub 2020 Sep 15. Leukemia. 2021. PMID: 32934355
Synthesis of new piperazinyl-pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of Candida albicans multidrug transporters by a Buchwald-Hartwig cross-coupling reaction.
Guillon J, Nim S, Moreau S, Ronga L, Savrimoutou S, Thivet E, Marchivie M, Di Pietro A, Prasad R, Le Borgne M. Guillon J, et al. Among authors: moreau s. RSC Adv. 2020 Jan 15;10(5):2915-2931. doi: 10.1039/c9ra09348f. eCollection 2020 Jan 14. RSC Adv. 2020. PMID: 35496110 Free PMC article.
52 results